Relationship of oxidative stress in the resistance to imatinib in Tunisian patients with chronic myeloid leukemia: A retrospective study.
Adult
Advanced Oxidation Protein Products
/ blood
Antineoplastic Agents
/ pharmacology
Antioxidants
/ metabolism
Ascorbic Acid
/ blood
Case-Control Studies
Drug Resistance, Neoplasm
/ drug effects
Enzymes
/ blood
Female
Glutathione
/ blood
Humans
Imatinib Mesylate
/ pharmacology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ drug therapy
Male
Malondialdehyde
/ blood
Middle Aged
Oxidative Stress
/ drug effects
Treatment Outcome
Tunisia
chronic myeloid leukemia
imatinib resistance
oxidative stress
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
24
05
2019
revised:
23
08
2019
accepted:
13
09
2019
pubmed:
17
10
2019
medline:
18
12
2020
entrez:
17
10
2019
Statut:
ppublish
Résumé
This work aimed to evaluate oxidative stress in chronic myeloid leukemia (CML) patients treated with tunisian (IM) vs controls and in CML patients with resistance to IM vs patients without resistance to IM. The study included 40 CML patients and 34 controls. Of 40 patients with CML, 26 patients were developed in resistance to IM. The oxidant/antioxidant markers were evaluated by spectrophotometric methods for all used samples. For CML patients, increased malondialdehyde (MDA) and advanced oxidation protein products (AOPP) levels were found compared to controls (P < .001; P = .01). Higher catalase (CAT) activity (P = .048) and lower superoxide dismutase (SOD) and glutathione peroxidase (GPx) activities, reduced Glutathione (GSH) and vitamin C levels were found in CML patients (P < .001). The comparison between the resistant vs no-resistant CML patients revealed higher MDA level (P = .02) and CAT and SOD activities in IM-resistant patients (P = .04, P = .03). GPx activity was reduced (P = .04). Furthermore, increased mean ratio of MDA/GSH, MDA/GPx, and SOD/(GPx + CAT) was found in IM-resistant patients as compared with no-resistant (P = .01, P = .01, P = .035). The mean ratio of GPx/GSH in the IM-resistant CML patients was lower than in IM no-resistant one (P = .039). For IM-resistant patients, we found negative correlation between MDA level and the ratio SOD/(CAT + GPx) (r = -0.46, P = .002); and positive correlation between SOD and (CAT + GPx) activities (r = 0.38, P = .06) and between GSH level and GPx activity (r = 0.53, P = .01). Our results have shown a highly disturbed oxidative profile in IM-resistant CML patients as compared to no-resistant. The H
Sections du résumé
BACKGROUND
BACKGROUND
This work aimed to evaluate oxidative stress in chronic myeloid leukemia (CML) patients treated with tunisian (IM) vs controls and in CML patients with resistance to IM vs patients without resistance to IM.
METHODS
METHODS
The study included 40 CML patients and 34 controls. Of 40 patients with CML, 26 patients were developed in resistance to IM. The oxidant/antioxidant markers were evaluated by spectrophotometric methods for all used samples.
RESULTS
RESULTS
For CML patients, increased malondialdehyde (MDA) and advanced oxidation protein products (AOPP) levels were found compared to controls (P < .001; P = .01). Higher catalase (CAT) activity (P = .048) and lower superoxide dismutase (SOD) and glutathione peroxidase (GPx) activities, reduced Glutathione (GSH) and vitamin C levels were found in CML patients (P < .001). The comparison between the resistant vs no-resistant CML patients revealed higher MDA level (P = .02) and CAT and SOD activities in IM-resistant patients (P = .04, P = .03). GPx activity was reduced (P = .04). Furthermore, increased mean ratio of MDA/GSH, MDA/GPx, and SOD/(GPx + CAT) was found in IM-resistant patients as compared with no-resistant (P = .01, P = .01, P = .035). The mean ratio of GPx/GSH in the IM-resistant CML patients was lower than in IM no-resistant one (P = .039). For IM-resistant patients, we found negative correlation between MDA level and the ratio SOD/(CAT + GPx) (r = -0.46, P = .002); and positive correlation between SOD and (CAT + GPx) activities (r = 0.38, P = .06) and between GSH level and GPx activity (r = 0.53, P = .01).
CONCLUSIONS
CONCLUSIONS
Our results have shown a highly disturbed oxidative profile in IM-resistant CML patients as compared to no-resistant. The H
Identifiants
pubmed: 31617242
doi: 10.1002/jcla.23050
pmc: PMC7031571
doi:
Substances chimiques
Advanced Oxidation Protein Products
0
Antineoplastic Agents
0
Antioxidants
0
Enzymes
0
Malondialdehyde
4Y8F71G49Q
Imatinib Mesylate
8A1O1M485B
Glutathione
GAN16C9B8O
Ascorbic Acid
PQ6CK8PD0R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e23050Informations de copyright
© 2019 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals, Inc.
Références
Singapore Med J. 2010 Feb;51(2):110-5
pubmed: 20358148
Indian J Clin Biochem. 2008 Oct;23(4):328-33
pubmed: 23105780
Blood. 2006 Jul 1;108(1):319-27
pubmed: 16527898
Blood. 2005 Feb 15;105(4):1717-23
pubmed: 15486067
Cancer Chemother Pharmacol. 2017 Apr;79(4):737-745
pubmed: 28286932
Leukemia. 2010 Jun;24(6):1105-12
pubmed: 20445577
Oncotarget. 2017 Jun 27;8(26):41876-41889
pubmed: 27566554
Blood. 2003 May 15;101(10):4098-104
pubmed: 12531810
Blood. 2011 Aug 4;118(5):1208-15
pubmed: 21562040
Asian Pac J Cancer Prev. 2016;17(9):4267-4273
pubmed: 27797229
J Exp Clin Cancer Res. 2014 Dec 18;33:106
pubmed: 25519934
Oxid Med Cell Longev. 2017;2017:8416763
pubmed: 28819546
Mutat Res. 2011 Jun 3;711(1-2):193-201
pubmed: 21216256
Leukemia. 2002 Nov;16(11):2190-6
pubmed: 12399961
Methods Enzymol. 1984;105:121-6
pubmed: 6727660
FASEB J. 2003 Jul;17(10):1195-214
pubmed: 12832285
Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):323-34
pubmed: 25971713
Leukemia. 2008 Jun;22(6):1191-9
pubmed: 18385754
Leukemia. 2009 Jun;23(6):1054-61
pubmed: 19282833
Methods Enzymol. 1978;52:302-10
pubmed: 672633
Lancet Oncol. 2007 Nov;8(11):1018-29
pubmed: 17976612
Acta Biochim Pol. 2016;63(2):365-70
pubmed: 26757169
Anal Biochem. 1971 Nov;44(1):276-87
pubmed: 4943714
Biochem J. 2009 Feb 15;418(1):29-37
pubmed: 18937644
Lancet. 1994 Sep 10;344(8924):721-4
pubmed: 7915779
N Engl J Med. 2006 Dec 7;355(23):2408-17
pubmed: 17151364
Methods Enzymol. 1984;105:114-21
pubmed: 6727659
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
Nutrients. 2019 Feb 13;11(2):
pubmed: 30781873
Cancer Cell. 2002 Aug;2(2):117-25
pubmed: 12204532
Cancer Sci. 2012 Jan;103(1):88-99
pubmed: 21943109
Oncogene. 2007 Jan 4;26(1):11-20
pubmed: 16785987
Cell Biochem Funct. 2002 Dec;20(4):327-31
pubmed: 12415567
In Vivo. 2008 Jul-Aug;22(4):525-8
pubmed: 18712183
Anal Biochem. 1982 Nov 15;127(1):178-82
pubmed: 7165085
Biochim Biophys Acta. 2012 Oct;1822(10):1527-34
pubmed: 22683338
Leuk Lymphoma. 2008 Apr;49(4):610-4
pubmed: 18398719
Clin Biochem. 2007 Sep;40(13-14):1015-9
pubmed: 17628517
Cancer Lett. 1988 Jun 30;40(3):257-64
pubmed: 3289734
Int J Mol Sci. 2015 Aug 05;16(8):18111-28
pubmed: 26251899
N Engl J Med. 2002 Feb 28;346(9):683-93
pubmed: 11870247
Leukemia. 2016 Aug;30(8):1648-71
pubmed: 27121688
Cell Biochem Funct. 2006 Jan-Feb;24(1):79-85
pubmed: 15532093
J Biol Chem. 2000 Aug 11;275(32):24273-8
pubmed: 10833515
Blood. 2006 Mar 15;107(6):2501-6
pubmed: 16291594
PLoS One. 2011;6(7):e21924
pubmed: 21789194
Blood. 2013 May 16;121(20):4175-83
pubmed: 23543457
Cancer Res. 2005 Jun 1;65(11):4500-5
pubmed: 15930265
Blood. 2011 Jun 2;117(22):5816-26
pubmed: 21398578
Am J Hematol. 2018 Mar;93(3):442-459
pubmed: 29411417
J Pediatr Hematol Oncol. 2017 Apr;39(3):e124-e130
pubmed: 28306688
J Clin Lab Anal. 2020 Feb;34(2):e23050
pubmed: 31617242